{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T19:24:27Z","timestamp":1751397867840},"reference-count":36,"publisher":"Japan Atherosclerosis Society","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Atheroscler Thromb","JAT"],"published-print":{"date-parts":[[2017]]},"DOI":"10.5551\/jat.32615","type":"journal-article","created":{"date-parts":[[2016,8,3]],"date-time":"2016-08-03T22:04:42Z","timestamp":1470261882000},"page":"123-132","source":"Crossref","is-referenced-by-count":11,"title":["Enhanced Impact of Cholesterol Absorption Marker on New Atherosclerotic Lesion Progression After Coronary Intervention During Statin Therapy"],"prefix":"10.5551","volume":"24","author":[{"given":"Kenta","family":"Mori","sequence":"first","affiliation":[{"name":"Division of Cardiovascular Medicine, Kobe University Graduate School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuro","family":"Ishida","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Kobe University Graduate School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeyasu","family":"Tsuda","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Kobe University Graduate School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshihiko","family":"Oshita","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Kobe University Graduate School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masakazu","family":"Shinohara","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Kobe University Graduate School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuya","family":"Hara","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Kobe University Graduate School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiro","family":"Irino","sequence":"additional","affiliation":[{"name":"Division of Evidence-based Laboratory Medicine, Kobe University Graduate School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryuji","family":"Toh","sequence":"additional","affiliation":[{"name":"Division of Evidence-based Laboratory Medicine, Kobe University Graduate School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken-ichi","family":"Hirata","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Kobe University Graduate School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3489","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Cholesterol Treatment Trialists&apos; (CTT) Collaboration. Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J, and Collins R: Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet, 2010; 376: 1670-1681","DOI":"10.1016\/S0140-6736(10)61350-5"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, Gotto AM, Greten H, Kastelein JJ, Shepherd J, and Wenger NK; Treating to New Targets (TNT) Investigators: Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med, 2005; 352: 1425-1435","DOI":"10.1056\/NEJMoa050461"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Chapman MJ, Redfern JS, McGovern ME, and Giral P: Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk. Pharmacol Ther, 2010; 126: 314-345","DOI":"10.1016\/j.pharmthera.2010.01.008"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Miettinen TA, Gylling H, Lindbohm N, Miettinen TE, Rajaratnam RA, and Relas H; Finnish Treat-to-Target Study Investigators: Serum noncholesterol sterols during inhibition of cholesterol synthesis by statins. J Lab Clin Med, 2003; 141: 131-137","DOI":"10.1067\/mlc.2003.9"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Hoshiga M, Arishiro K, Nakakoji T, Miyazaki N, Negoro N, Okabe T, Kohbayashi E, Ishihara T, and Hanafusa T: Switching to aggressive statin improves vascular endothelial function in patients with stable coronary artery disease. J Atheroscler Thromb, 2010; 17: 705-711","DOI":"10.5551\/jat.3848"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Kesaniemi YA, and Miettinen TA: Cholesterol absorption efficiency regulates plasma cholesterol level in the Finnish population. Eur J Clin Invest, 1987; 17: 391-395","DOI":"10.1111\/j.1365-2362.1987.tb01132.x"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Strandberg TE, Tilvis RS, Pitkala KH, and Miettinen TA: Cholesterol and glucose metabolism and recurrent cardiovascular events among the elderly: a prospective study. J Am Coll Cardiol, 2006; 48: 708-714","DOI":"10.1016\/j.jacc.2006.04.081"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Miettinen TA, Gylling H, Strandberg T, and Sarna S: Baseline serum cholestanol as predictor of recurrent coronary events in subgroup of Scandinavian simvastatin survival study. Finnish 4S Investigators. BMJ, 1998; 316: 1127-1130","DOI":"10.1136\/bmj.316.7138.1127"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Matthan NR, Pencina M, LaRocque JM, Jacques PF, D&apos;Agostino RB, Schaefer EJ, and Lichtenstein AH: Alterations in cholesterol absorption\/synthesis markers characterize Framingham offspring study participants with CHD. J Lipid Res, 2009; 50: 1927-1935","DOI":"10.1194\/jlr.P900039-JLR200"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Silbernagel G, Fauler G, Genser B, Drechsler C, Krane V, Scharnagl H, Grammer TB, Baumgartner I, Ritz E, Wanner C, and Marz W: Intestinal cholesterol absorption, treatment with atorvastatin, and cardiovascular risk in hemodialysis patients. J Am Coll Cardiol, 2015; 65: 2291-2298","DOI":"10.1016\/j.jacc.2015.03.551"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, Darius H, Lewis BS, Ophuis TO, Jukema JW, De Ferrari GM, Ruzyllo W, De Lucca P, Im K, Bohula EA, Reist C, Wiviott SD, Tershakovec AM, Musliner TA, Braunwald E, Califf RM and Investigators I-I: Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med, 2015; 372: 2387-2397","DOI":"10.1056\/NEJMoa1410489"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Masuda D, Nishida M, Arai T, Hanada H, Yoshida H, Yamauchi-Takihara K, Moriyama T, Tada N and Yamashita S: Reference interval for the apolipoprotein B-48 concentration in healthy Japanese individuals. J Atheroscler Thromb, 2014; 21: 618-627","DOI":"10.5551\/jat.22558"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Mori K, Ishida T, Yasuda T, Hasokawa M, Monguchi T, Sasaki M, Kondo K, Nakajima H, Shinohara M, Shinke T, Irino Y, Toh R, Nishimura K, and Hirata KI: Serum trans-fatty acid concentration is elevated in young patients with coronary artery disease in Japan. Circ J, 2015; 79: 2017-2025","DOI":"10.1253\/circj.CJ-14-0750"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) JCS Joint Working Group: Guidelines for Secondary Prevention of Myocardial Infarction (JCS 2011). Circ J, 2013; 77: 231-248","DOI":"10.1253\/circj.CJ-66-0053"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) D&apos;Agostino RB Sr, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, and Kannel WB: General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation, 2008; 117: 743-753","DOI":"10.1161\/CIRCULATIONAHA.107.699579"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Gylling H, and Miettinen TA: Cholesterol absorption and lipoprotein metabolism in type II diabetes mellitus with and without coronary artery disease. Atherosclerosis, 1996; 126: 325-332","DOI":"10.1016\/0021-9150(96)05930-8"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Rogacev KS, Pinsdorf T, Weingartner O, Gerhart MK, Welzel E, van Bentum K, Popp J, Menzner A, Fliser D, Lutjohann D, and Heine GH: Cholesterol synthesis, cholesterol absorption, and mortality in hemodialysis patients. Clin J Am Soc Nephrol, 2012; 7: 943-948","DOI":"10.2215\/CJN.05170511"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Lally S, Tan CY, Owens D, and Tomkin GH: Messenger RNA levels of genes involved in dysregulation of postprandial lipoproteins in type 2 diabetes: the role of Niemann-Pick C1-like 1, ATP-binding cassette, transporters G5 and G8, and of microsomal triglyceride transfer protein. Diabetologia, 2006; 49: 1008-1016","DOI":"10.1007\/s00125-006-0177-8"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Nasu K, Terashima M, Habara M, Ko E, Ito T, Yokota D, Ishizuka S, Kurita T, Kimura M, Kinoshita Y, Asakura Y, Tsuchikane E, Katoh O, and Suzuki T: Impact of cholesterol metabolism on coronary plaque vulnerability of target vessels: a combined analysis of virtual histology intravascular ultrasound and optical coherence tomography. JACC Cardiovasc Interv, 2013; 6: 746-755","DOI":"10.1016\/j.jcin.2013.02.018"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Tsujita K, Sugiyama S, Sumida H, Shimomura H, Yamashita T, Yamanaga K, Komura N, Sakamoto K, Oka H, Nakao K, Nakamura S, Ishihara M, Matsui K, Sakaino N, Nakamura N, Yamamoto N, Koide S, Matsumura T, Fujimoto K, Tsunoda R, Morikami Y, Matsuyama K, Oshima S, Kaikita K, Hokimoto S, Ogawa H and Investigators P-I: Impact of Dual Lipid-Lowering Strategy With Ezetimibe and Atorvastatin on Coronary Plaque Regression in Patients With Percutaneous Coronary Intervention: The Multicenter Randomized Controlled PRECISEIVUS Trial. J Am Coll Cardiol, 2015; 66: 495-507","DOI":"10.1016\/j.jacc.2015.05.065"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Otaegui-Arrazola A, Menendez-Carreno M, Ansorena D, and Astiasaran I: Oxysterols: A world to explore. Food Chem Toxicol, 2010; 48: 3289-3303","DOI":"10.1016\/j.fct.2010.09.023"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Staprans I, Pan XM, Rapp JH, Moser AH, and Feingold KR: Ezetimibe inhibits the incorporation of dietary oxidized cholesterol into lipoproteins. J Lipid Res, 2006; 47: 2575-2580","DOI":"10.1194\/jlr.M600261-JLR200"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Endo K, Oyama T, Saiki A, Ban N, Ohira M, Koide N, Murano T, Watanabe H, Nishii M, Miura M, Sekine K, Miyashita Y, and Shirai K: Determination of serum 7-ketocholesterol concentrations and their relationships with coronary multiple risks in diabetes mellitus. Diabetes Res Clin Pract, 2008; 80: 63-68","DOI":"10.1016\/j.diabres.2007.10.023"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Connor WE, and Connor SL: The key role of nutritional factors in the prevention of coronary heart disease. Prev Med, 1972; 1: 49-83","DOI":"10.1016\/0091-7435(72)90077-1"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Katan MB, Beynen AC, de Vries JH, and Nobels A: Existence of consistent hypo- and hyperresponders to dietary cholesterol in man. Am J Epidemiol, 1986; 123: 221-234","DOI":"10.1093\/oxfordjournals.aje.a114231"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Hegele RA, Guy J, Ban MR, and Wang J: NPC1L1 haplotype is associated with inter-individual variation in plasma low-density lipoprotein response to ezetimibe. Lipids Health Dis, 2005; 4: 16","DOI":"10.1186\/1476-511X-4-16"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Ziajka PE, Reis M, Kreul S, and King H: Initial low-density lipoprotein response to statin therapy predicts subsequent low-density lipoprotein response to the addition of ezetimibe. Am J Cardiol, 2004; 93: 779-780","DOI":"10.1016\/j.amjcard.2003.11.060"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Pisciotta L, Fasano T, Bellocchio A, Bocchi L, Sallo R, Fresa R, Colangeli I, Cantafora A, Calandra S, and Bertolini S: Effect of ezetimibe coadministered with statins in genotype-confirmed heterozygous FH patients. Atherosclerosis, 2007; 194: e116-122","DOI":"10.1016\/j.atherosclerosis.2006.10.036"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Myocardial Infarction Genetics Consortium I, Stitziel NO, Won HH, Morrison AC, Peloso GM, Do R, Lange LA, Fontanillas P, Gupta N, Duga S, Goel A, Farrall M, Saleheen D, Ferrario P, Konig I, Asselta R, Merlini PA, Marziliano N, Notarangelo MF, Schick U, Auer P, Assimes TL, Reilly M, Wilensky R, Rader DJ, Hovingh GK, Meitinger T, Kessler T, Kastrati A, Laugwitz KL, Siscovick D, Rotter JI, Hazen SL, Tracy R, Cresci S, Spertus J, Jackson R, Schwartz SM, Natarajan P, Crosby J, Muzny D, Ballantyne C, Rich SS, O&apos;Donnell CJ, Abecasis G, Sunyaev S, Nickerson DA, Buring JE, Ridker PM, Chasman DI, Austin E, Ye Z, Kullo IJ, Weeke PE, Shaffer CM, Bastarache LA, Denny JC, Roden DM, Palmer C, Deloukas P, Lin DY, Tang ZZ, Erdmann J, Schunkert H, Danesh J, Marrugat J, Elosua R, Ardissino D, McPherson R, Watkins H, Reiner AP, Wilson JG, Altshuler D, Gibbs RA, Lander ES, Boerwinkle E, Gabriel S, and Kathiresan S: Inactivating mutations in NPC1L1 and protection from coronary heart disease. N Engl J Med, 2014; 371: 2072-2082","DOI":"10.1056\/NEJMoa1405386"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Buchwald H, Varco RL, Matts JP, Long JM, Fitch LL, Campbell GS, Pearce MB, Yellin AE, Edmiston WA, Smink RD Jr, et al.: Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH). N Engl J Med, 1990; 323: 946-955","DOI":"10.1056\/NEJM199010043231404"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Masuda D, Sugimoto T, Tsujii K, Inagaki M, Nakatani K, Yuasa-Kawase M, Tsubakio-Yamamoto K, Ohama T, Nishida M, Ishigami M, Kawamoto T, Matsuyama A, Sakai N, Komuro I and Yamashita S: Correlation of fasting serum apolipoprotein B-48 with coronary artery disease prevalence. Eur J Clin Invest, 2012; 42: 992-999","DOI":"10.1111\/j.1365-2362.2012.02687.x"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) Mori K, Ishida T, Yasuda T, Monguchi T, Sasaki M, Kondo K, Hasokawa M, Nakajima H, Haraguchi Y, Sun L, Shinohara M, Toh R, Nishimura K, and Hirata K: Fasting serum concentration of apolipoprotein B48 represents residual risks in patients with new-onset and chronic coronary artery disease. Clin Chim Acta, 2013; 421: 51-56","DOI":"10.1016\/j.cca.2013.02.005"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33) Sonoda M, Shoji T, Kimoto E, Okute Y, Shima H, Naganuma T, Motoyama K, Morioka T, Mori K, Fukumoto S, Shioi A, Koyama H, Emoto M and Inaba M: Kidney function, cholesterol absorption and remnant lipoprotein accumulation in patients with diabetes mellitus. J Atheroscler Thromb, 2014; 21: 346-354","DOI":"10.5551\/jat.20594"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34) Taggart C, Gibney J, Owens D, Collins P, Johnson A, Tomkin GH. The role of dietary cholesterol in the regulation of postprandial apolipoprotein B48 levels in diabetes. Diabet Med, 1997; 14: 1051-1058","DOI":"10.1002\/(SICI)1096-9136(199712)14:12<1051::AID-DIA507>3.0.CO;2-Q"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35) Rashid S, Tavori H, Brown PE, Linton MF, He J, Giunzioni I, Fazio S. Proprotein convertase subtilisin kexin type 9 promotes intestinal overproduction of triglyceride-rich apolipoprotein B lipoproteins through both low-density lipoprotein receptor-dependent and\u2013independent. Circulation, 2014; 130: 431-441","DOI":"10.1161\/CIRCULATIONAHA.113.006720"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36) Cariou B, Le May C, Costet P. Clinical aspects of PCSK9. Atherosclerosis 2011; 216: 258-265","DOI":"10.1016\/j.atherosclerosis.2011.04.018"}],"container-title":["Journal of Atherosclerosis and Thrombosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/24\/2\/24_32615\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,12]],"date-time":"2019-09-12T04:00:36Z","timestamp":1568260836000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/24\/2\/24_32615\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.5551\/jat.32615","relation":{},"ISSN":["1340-3478","1880-3873"],"issn-type":[{"value":"1340-3478","type":"print"},{"value":"1880-3873","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017]]}}}